competition gravitates towards the first-line setting, how do KOLs compare and contrast the multitude of combination regimens vying for approval in this lucrative indication? Immunotherapies are still lagging behind in ovarian cancer, compared with certain other malignancies, but which key trials could finally place them on map? Twelve of the world’s leading KOLs from the US and Europe offer candid insights on four marketed therapies and nine Phase III drugs.

Top takeaways:

Could first-line treatment become the next battleground for novel treatment strategies in ovarian cancer? With a number of companies investing in multiple combination regimens, who could emerge victorious?

What potential do immune checkpoint inhibitors hold in the future treatment of ovarian cancer?

Roche, Merck Group and Pfizer are heavily invested in this area, but how do KOLs rate the prospects for combination regimens containing avelumab or atezolizumab? 

PARP inhibitors comprise a cornerstone of treatment for advanced ovarian cancer?How do KOLs see their use evolving?
 
AstraZeneca/Merck & Co.’s Lynparza is well established in relapsed disease. But is increasing competition, or the outcome of the PAOLA-1 trial, likely to impact its use? 

As the treatment paradigm matures and PARP inhibitors gain a broader role, what do KOLs see as the key threats and opportunities for Tesaro/Merck & Co.’s Zejula and Clovis’ Rubraca? 

Roche’s Avastin is firmly entrenched in the treatment algorithm for ovarian cancer. But what opportunities and threats lie ahead? 

Allergan/Amgen’s Mvasi is making headlines as the first bevacizumab biosimilar to gain approval. How well accepted will it be among oncologists who treat ovarian cancer and how is pricing likely to influence uptake? 

Marketed Therapies:
Lynparza (olaparib; AstraZeneca/Merck & Co.)
Zejula (niraparib; Tesaro/Merck & Co. )
Rubraca (rucaparib; Clovis) 
Avastin (bevacizumab; Roche) 
Phase III Therapies
Veliparib (ABT-888; AbbVie)
Atezolizumab (Tecentriq; Roche) 
Avelumab (Bavencio; Merck Group/Pfizer) 
Vigil (autologous tumour cell vaccine; Gradalis) 
Nintedanib (Vargatef; Boehringer Ingelheim) 
Ofranergene obadenovec (VB-111; VBL Therapeutics) 
Mvasi (bevacizumab biosimilar; Allergan/Amgen) 
Masitinib (AB Science) 

KOLs from North America:
Ronald Alvarez,Professor and Chairman of the Department of Obstetrics & Gynaecology, Vanderbilt University Medical Centre, Nashville, TN. 
Michael J. Birrer, Professor and Director, Gynaecologic Medical Oncology Massachusetts General Hospital Leader, DF/HCC Gynaecologic Cancers Program, Boston, MA. 
Robert A. Burger,Professor of Obstetrics & Gynaecology, Director of Clinical Research and Fellowship Program in Gynaecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA. 
KOLs from Europe
Stan Kaye, Professor and Consultant Medical Oncologist, Head of the Division of Clinical Studies at the Institute of Cancer Research, London, UK. 
Jean-Emmanuel Kurtz, Professor and hospital practitioner at the University of Strasbourg/ University Hospital Strasbourg, Strasbourg, France. 
Christian Marth, Director of Obstetrics and Gynaecology, University Hospital Innsbruck, Innsbruck, Austria. 
Sandro Pignata, Head of Uro-Gynaecological Department, Division of Medical Oncology, IRCCS National Cancer Institute, Naples, Italy. 

For more details visit link: https://www.aarkstore.com/healthcare/960262/ovarian-cancer-kol-insight

Category: Healthacre Market Research
Aarkstore Enterprise
+91 9987295242 | [email protected] | aarkstore.com